Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

Circulation

Volumn 108, Issue 4, 2003, Pages 399-406

  Topol, Eric J ^a   Easton, Donald ^b   Harrington, Robert A ^c   Amarenco, Pierre ^d   Califf, Robert M ^c   Graffagnino, Carmen ^c   Davis, Stephen ^m   Diener, Hans Christophe ^e   Ferguson, James ^f   Fitzgerald, Desmond ^g   Granett, Jeffrey ^m   Shuaib, Ashfaq ^h   Koudstaal, Peter J ⁱ   Theroux, Pierre ^j   De Werf, Frans Van ^k   Sigmon, Kristina ^c   Pieper, Karen ^c   Vallee, Marc ^c   Willerson, James T ^l  

^a LERNER RESEARCH INSTITUTE   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d HÔPITAL LARIBOISIÈRE   (France)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f TEXAS HEART INSTITUTE   (United States)

^g ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j MONTREAL HEART INSTITUTE   (Canada)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^m NONE

more..

Author keywords

Antiplatelets; Atherosclerosis; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; FIBRINOGEN RECEPTOR ANTAGONIST; LOTRAFIBAN; PLACEBO; THIENO[2,3 D]PYRIMIDINE DERIVATIVE; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE; THROMBOCYTE; THROMBOSIS;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BENZODIAZEPINES; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PIPERIDINES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0043166526     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000084501.48570.F6     Document Type: Article

References (13)

1. Kong, DF, Califf RM, Miller OP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
2. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149-156.
3. O'Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization: EXCITE Trial Investigator: Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med. 2000;342:1316-1324.
4. SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial: Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes. Lancet. 2000;355:337-345.
5. The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, of both to prevent ischemic events after acute coronary syndromes. Circulation. 2001;103:1727-1733.
6. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein Ilb/IIIa antagonists: a meta-analysis of the phase III multicenter randomized trials. Circulation. 2001;103:201-206.
7. Harrington RA, Armstrong PW, Graffagnino C, et al, for the Anti-Platelet Useful Dose (APLAUD) Study Investigators. Dose-finding, safety, and tolerability of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary of cerebral atherosclerotic disease. Circulation. 2000;102:728-735.
8. Topol EJ, Easton D, Amarenco P, et al. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Am Heart J. 2000;139:927-933.
9. Holmes M, Sobel BE, Cannon CP, et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 sub-study. Am J Cardiol. 2000;85:491-493.
10. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation. 2002;106:379-385.
11. Andre P, Nannizzi-Alaimo L, Prasad SK, et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:996-997.
12. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107:1123-1128.
13. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack of minor ischemic stroke. N Engl J Med. 1991;325:1261-1266.